Histopathological and Immunohistochemical Evaluation of Malignant Ovarian Tumours


  • Motia Kanwal Department of Histopathology, Army Medical College/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
  • Tariq Sarfraz Department of Histopathology, Army Medical College/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
  • Hina Tariq Department of Histopathology, Army Medical College/National University of Medical Sciences (NUMS) Rawalpindi Pakistan




Histopathology, Granulosa cell tumor, Dysgerminoma Leydig cell tumor, Ovarian neoplasms, Sertoli cell tumor


Objective: To determine the frequency and histological types of malignant ovarian tumours using morphological features and immunohistochemistry.

Study Design: Cross-sectional study.

Place and Duration of Study: Department of Histopathology, Army Medical College, Rawalpindi Pakistan, Jan 2016 to Dec

Methodology: Newly diagnosed cases of malignant ovarian tumour who had not received chemotherapy were included.
Cases of benign ovarian tumours and those who were treated with pre-surgical chemotherapy were excluded.

Results: In total, 118 cases of malignant ovarian tumours were evaluated. High-grade serous carcinomas were 61(51.7%),
which outnumber others, followed by granulosa cell tumours 17(14.4%), germ cell tumours 13(11%), endometrioid carcinoma 9(7.6%), clear cell carcinoma 4(3.4%), mucinous carcinoma 4(3.4%), low-grade serous carcinoma 2(1.7%) and carcinosarcoma in one case (0.8%). Cancer in the ovary was metastatic in 7(5.9%) cases. No Sertoli Leydig cell tumour, malignant Brenner tumour, embryonal carcinoma or immature teratomas were diagnosed.

Conclusion: Surface epithelial tumours were the most common malignancy, followed by granulosa cell tumours and
dysgerminoma. An increase in the frequency of ovarian tumours in younger age groups was also noted. Immunohistochemistry was a useful adjuvant diagnostic tool in cases of ovarian malignancy. Metastases to the ovary were
mostly gastrointestinal in origin.


Download data is not yet available.


Metrics Loading ...


Stewart SL. Ovarian Cancer Incidence: Current and

Comprehensive Statistics. Ovarian Cancer - Clinical and

Therapeutic Perspectives. IntechOpen Limited, London; 2012.


Kommoss S, Gilks CB, du Bois A, Kommoss F. Ovarian carcinoma

diagnosis: the clinical impact of 15 years of change. Br J Cancer

; 115(8): 993-999. http://doi.org/10.1038/bjc.2016.273.

Verma N, Kumar M, Sagar M, Babu S, Singhai A, Singh N, et al.

Expression of estrogen receptor, progesterone receptor, and

human epidermal growth factor receptor type 2/neu in surface

epithelial ovarian tumors and its clinichistopathological

correlation. Indian J Health Sci Biomed Res 2018; 11(1):19.

Duraiyan J, Govindarajan R, Kaliyappan K. Applications of

immunohistochemistry. J Pharm Bioallied Sci 2012; 4(Suppl 2):

S307-309. http://doi.org/10.4103/0975-7406.100281.

Yemelyanova AV, Vang R, Judson K, Wu LS, Ronnett BM.

Distinction of primary and metastatic mucinous tumors

involving the ovary: analysis of size and laterality data by

primary site with reevaluation of an algorithm for tumor

classification. Am J Surg Pathol 2008; 32(1): 128-138.


Coburn SB, Bray F, Sherman ME, Trabert B. International patterns

and trends in ovarian cancer incidence, overall and by histologic

subtype. Int J Cancer 2017; 140(11): 2451-2460.


Köbel M, Rahimi K, Rambau PF, Naugler C, Le Page C, Meunier L,

et al. An immunohistochemical algorithm for ovarian carcinoma

typing. Int J Gynecol Pathol 2016; 35(5): 430-441.


Lin F, Liu H. Immunohistochemistry in undifferentiated

neoplasm/tumor of uncertain origin. Arch Pathol Lab Med 2014;

(12): 1583-1610. http://doi.org/10.5858/arpa.2014-0061-RA.

Sheikh S, Bashir H, Farooq S, Beigh A, Manzoor F, Reshi R, et al.

Histopathological spectrum of ovarian tumours from a referral

hospital in Kashmir valley, Jammu and Kashmir, India. Int J Res

Med Sci 2017; 5(5): 2110–2114.


Patel AS, Patel JM, Shah KJ. Ovarian tumors-Incidence and

histopathological spectrum in tertiary care center, Valsad. Int

Arch Integr Med 2018; 5(2): 84-93.

Zubair M, Hashmi SN, Afzal S, Muhammad I, Din HU, Hamdani

SN. Ovarian Tumours: A study of 2146 Cases at AFIP,

Rawalpindi, Pakistan. Aust Asian J Cancer 2015; 14(1): 21-26.

Razi S, Ghoncheh M, Mohammadian-Hafshejani A, Aziznejhad

H, Mohammadian M, Salehiniya H. The incidence and mortality

of ovarian cancer and their relationship with the Human

Development Index in Asia. Ecancermedicalscience 2016; 10: 628.


Zhao L, Guo M, Sneige N, Gong Y. Value of PAX8 and WT1

Immunostaining in Confirming the Ovarian Origin of Metastatic

Carcinoma in Serous Effusion Specimens. Am J Clin Pathol 2012;

(2): 304-309.


Kommoss F, Gilks CB. Pathology of Ovarian Cancer: Recent

Insights Unveiling Opportunities in Prevention. Clin Obstet

Gynecol 2017; 60(4): 686-696.


Jelovac D, Armstrong DK. Recent progress in the diagnosis and

treatment of ovarian cancer. CA Cancer J Clin 2011; 61(3): 183-


Köbel M, Bak J, Bertelsen BI, Carpen O, Grove A, Hansen ES, et

al. Ovarian carcinoma histotype determination is highly

reproducible, and is improved through the use of

immunohistochemistry. Histopathology 2014; 64(7): 1004-1013.


Hashmi AA, Hussain ZF, Bhagwani AR, Edhi MM, Faridi N,

Hussain SD, et al. Clinicopathologic features of ovarian

neoplasms with emphasis on borderline ovarian tumors: an

institutional perspective. BMC Res Notes 2016; 9: 205.


Nishal AJ, Naik KS, Modi J. Analysis of spectrum of ovarian

tumours: a study of 55 cases. Int J Res Med Sci 2015; 3(10): 2714-


Modepalli N, Venugopal SB. Clinicopathological Study of Surface

Epithelial Tumours of the Ovary: An Institutional Study. J Clin

Diagn Res 2016; 10(10): EC01-EC04.


Li Q, Zeng X, Cheng X, Zhang J, Ji J, Wang J, et al. Diagnostic

value of dual detection of hepatocyte nuclear factor 1 beta (HNF1β) and napsin A for diagnosing ovarian clear cell carcinoma. Int

J Clin Exp Pathol 2015; 8(7): 8305-8310.

Kao YC, Lin MC, Lin WC, Jeng YM, Mao TL. Utility of hepatocyte

nuclear factor‐1β as a diagnostic marker in ovarian carcinomas

with clear cells. Histopathology 2012; 61(5): 760-768.


DeLair D, Han G, Irving JA, Leung S, Ewanowich CA, Longacre

TA, et al. HNF-1β in ovarian carcinomas with serous and clear

cell change. Int J Gynecol Pathol 2013; 32(6): 541-546.





How to Cite

Kanwal, M., Sarfraz, T., & Tariq, H. (2024). Histopathological and Immunohistochemical Evaluation of Malignant Ovarian Tumours. Pakistan Armed Forces Medical Journal, 74(1), 26–30. https://doi.org/10.51253/pafmj.v74i1.5949



Original Articles

Most read articles by the same author(s)

1 2 3 > >>